PATENTES FARMACÊUTICAS E DIREITO À VIDA.

Abstract

This research was made through an examination of pharmaceutical patents, important instrument of protection to new drug discovery and manufacturing processes. The pharmaceutical patent today is important protagonist of controversy regarding its economic conflict with the right to life. With globalization, intellectual property is no longer relevant to the domestic law only to fill an important place in the agenda of International Relations, generating conflicts, debates, disputes and key element in the characterization of policies for the trade issue. The pharmaceutical market has unique characteristics, such as need for large investments, rigid quality control, momentary benefit, high risk and very competitive. Chagas disease, sleeping sickness, Leishmaniasis, Malaria, Yellow Fever, Tuberculosis, Dengue, Leprosy diseases are despised by large laboratories, which have large commercial interests, keeping oligopolies in developed countries. Is done in this research reflects on the relevance of patents in the war between the major laboratories and developing and Third World countries. The emphasis on Influenza vaccine is due to the commitment of the WHO (World Health Organization) to fight worldwide, preferably in winter, requiring extensive work by laboratories such as Sanofi Pasteur that produces Vaxigrip® and Fluzone®. The overall objective of this research is to analyze the actual need of the patent referred opposite the conflict with the right to life to cause economic impediment to the treatment of certain ailments. It is concluded that the patenteárea protection proves to be essential for the proper and efficient maintenance of the right to life, the fundamental guarantee of humanity, becoming this protection, by extension, a moral obligation of the States, leaving the same principles as the use of compulsory license to penalize any economic abuse, as provided in the new national legislation.